-=La Jolla Pharmaceutical (LJPC) reported earnings on Wed 24 Oct 2018 (a/h)

La Jolla Pharm reports Q3 EPS of ($1.93) vs ($2.01) consensus; revs +118.8% y/y to $3.5 mln vs $3.4 mln consensus; expects to have sufficient cash to fund ops at least into 2H 2020

SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Wednesday reported a loss of $50.7 million in its third quarter.

The San Diego-based company said it had a loss of $1.93 per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $2.01 per share.

The drugmaker posted revenue of $3.5 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $3.4 million.

La Jolla Pharmaceutical shares have fallen 53 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $15.23, a drop of 54 percent in the last 12 months.

-=La Jolla Pharma (LJPC) reported earnings on Thur 26 Oct 2017 (a/h)

La Jolla Pharma beats by $0.07 

• Reports Q3 (Sep) loss of $1.19 per share, $0.07 better than the Capital IQ Consensus of ($1.26).
• The San Diego-based company reported a loss of $26.3 million in its third quarter.
• As of September 30, 2017, the Company had $120.8 million in cash and cash equivalents, compared to $65.7 million of cash and cash equivalents at December 31, 2016. Cash used in operating activities for the nine months ended September 30, 2017 was $60.4 million, compared to $40.1 million for the same period in 2016.